Poolbeg Pharma plc - POLB 001 Patent Granted in United States

Further strengthens Poolbeg's robust intellectual property portfolio

20 November 2024- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the US Patent Office has notified the Company of its official decision to grant Poolbeg's US Immunomodulator I patent application.

The claims cover POLB 001, and other p38 MAP kinase inhibitors, for the treatment of patients at risk of severe influenza after an immune response has been triggered, and for the treatment of hypercytokinemia (cytokine storm) characteristic of severe influenza. POLB 001 is a potent and selective Phase II-ready p38 MAP kinase inhibitor with strong potential across multiple disease areas.

This patent grant further strengthens Poolbeg's robust Intellectual Property (IP) portfolio. The Company has patents in place covering p38 MAP kinase inhibitors for the treatment of severe influenza; and covering POLB 001 for the treatment of hypercytokinemia. Further patent applications have been filed and have complementary coverage as the Company continues to expand its patent portfolio covering POLB 001 and the wider class of p38 MAP kinase inhibitors, particularly in respect of cytokine release syndrome induced by cancer immunotherapies. Building a robust IP portfolio is a key focus for Poolbeg to further enhance POLB 001's value and attractiveness to potential partners.

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented: "This award by the US patent office further strengthens the IP for our lead development candidate, POLB 001. Strong IP is the foundation of value creation in biopharma, and with each new patent, we not only protect our asset but also increase the commercial appeal of POLB 001 to prospective partners. We are excited by the potential of POLB 001 to address critical unmet medical needs and we remain focused on high value programmes and partnerships to develop and commercialise our assets."

Enquiries 

About Poolbeg Pharma plc 

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on acquiring, developing and commercialising innovative medicines that will help improve the lives of patients with rare and orphan diseases and where there is a high unmet medical need. Poolbeg comprises a strong and growing portfolio of development assets. For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.